GlassScriptPhysician profile
Samer J Shaker
NPI 1194189266
$3,098.90
in general payments reported to CMS, 2019-2025
21 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,535 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.90 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $469.94 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $304.46 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $258.24 | 2024-2025 | |
| Exact Sciences Corporation | $237.92 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $219.85 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.82 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $141.35 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.03 | 2024-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $96.48 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $87.83 | 2024-2025 | Winrevair, Gardasil 9, Capvaxive |
| Amgen INC. | $70.21 | 2025 | Repatha |
| Glaxosmithkline, LLC. | $47.41 | 2024-2025 | Shingrix, Arexvy |
| Currax Pharmaceuticals LLC | $46.30 | 2024 | Contrave, Onzetra Xsail |
| Lundbeck LLC | $38.48 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $31.82 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $18.30 | 2024 | Xarelto |
| Sanofi Pasteur INC. | $18.19 | 2025 | |
| Phadia US INC. | $17.86 | 2024 | Immunocap |
| Xeris Pharmaceuticals, INC. | $17.25 | 2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $14.26 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Shaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.